Virginia Tech researchers discovered that some medium-chain fatty acids, present in certain infant formulas, can cause stress on the developing liver of newborn piglets. This finding suggests that these components may be related to the first signs of fatty liver disease in infants. The study showed that steatotic liver disease manifests differently in children and adults. While adults experience liver fat accumulation when fat burning decreases, newborn piglets showed fat accumulation even with an increase in fat metabolism.

Fats in Formulas

Researchers examined two different diets in infant formulas: one with medium-chain fatty acids, primarily from coconut oil, and another with long-chain fatty acids, derived from animal fat.

Piglets fed the medium-chain formula showed faster and more pronounced liver fat accumulation, indicating a need to reconsider the composition of infant formulas.

Implications for Infant Nutrition

Despite the findings, the study author stressed that the use of infant formulas should not be discouraged. The research aims to improve the composition of infant formulas through a deeper understanding of how the various components affect developing liver metabolism.

Federal agencies are reevaluating infant formula standards to ensure their safety and nutritional quality.

Long-term effects

The accumulation of liver fat (hepatic steatosis or fatty liver) in newborns is uncommon, but it can occur in premature or low birth weight infants, and is associated with early metabolic risks. In the long term, if it persists or progresses, it increases the risk of chronic liver and systemic complications.

Liver risks.

Simple steatosis is usually reversible, but it can progress to steatohepatitis (inflammation and cell damage), fibrosis, and, in severe cases, cirrhosis or liver cancer in adulthood. Children with this condition at birth are more likely to develop advanced liver disease compared to those who acquire it later in life. Metabolic impact: It increases the risk of childhood obesity, insulin resistance,type 2 diabetes, and dyslipidemia throughout life. Factors such as prematurity increase the chances of fatty liver 14-fold, while exclusive breastfeeding until 6 months acts as a protective factor. Monitoring and prevention: It requires lifelong hepatological follow-up to detect progression using ultrasound and liver enzymes. Early interventions, such as proper nutrition and weight management, mitigate risks.

You may also be interested in:

• Weight-loss drugs are just the beginning, not the solution to obesity• Potential of GLP-1 drugs to treat substance addictions being examined• Drug market war: Ozempic and Wegovy prices will be halved by 2027